Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 144 Records) |
| Query Trace: Neoplasms and CDK4[original query] |
|---|
| Efficacy and potential resistance mechanisms of afatinib in advanced non-small cell lung cancer patients with EGFR G719X/L861Q/S768I. Cancer 2022 Sep . Pang Lan-Lan, Gan Jia-Di, Tan Jia-Rong, Huang Yi-Hua, Liao Jun, Liang Wei-Ting, Deng Peng-Bo, Fang Wen-Fe |
| Hallmark-guided subtypes of hepatocellular carcinoma for the identification of immune-related gene classifiers in the prediction of prognosis, treatment efficacy, and drug candidates. Frontiers in immunology 2022 8 13 958161. Guo Chengbin, Tang Yuqin, Yang Zhao, Li Gen, Zhang Yongqia |
| Dissecting Molecular Heterogeneity of Circulating Tumor Cells (CTCs) from Metastatic Breast Cancer Patients through Copy Number Aberration (CNA) and Single Nucleotide Variant (SNV) Single Cell Analysis. Cancers 2022 8 14 (16): . Rossi Tania, Angeli Davide, Tebaldi Michela, Fici Pietro, Rossi Elisabetta, Rocca Andrea, Palleschi Michela, Maltoni Roberta, Martinelli Giovanni, Fabbri Francesco, Gallerani Giul |
| Targeting the FGF/FGFR axis and its co-alteration allies. ESMO open 2022 12 7 (6): 100647. Uehara Y, Ikeda S, Kim K H, Lim H J, Adashek J J, Persha H E, Okamura R, Lee S, Sicklick J K, Kato S, Kurzrock |
| Identification of TCR rearrangements specific for genetic alterations in EGFR-mutated non-small cell lung cancer: results from the ADJUVANT-CTONG1104 trial. Cancer immunology, immunotherapy : CII 2022 11 . Chen Cunte, Liu Siyang Maggie, Chen Yedan, Ou Qiuxiang, Bao Hua, Xu Ling, Zhang Yikai, Zhang Jia-Tao, Zhong Wenzhao, Zhou Qing, Yang Xue-Ning, Shao Yang, Wu Yi-Long, Liu Si-Yang, Li Yangq |
| Clinical outcomes of tucidinostat-based therapy after prior CDK4/6 inhibitor progression in hormone receptor-positive heavily pretreated metastatic breast cancer. Breast (Edinburgh, Scotland) 2022 11 66 255-261. Zhou Jinmei, Wu Xuexue, Zhang Huiqiang, Wang Xiaobo, Yuan Yang, Zhang Shaohua, Jiang Zefei, Wang T |
| APOBEC Mutational Signatures in Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy. JCO precision oncology 2022 10 6 e2200149. Sammons Sarah, Raskina Kira, Danziger Natalie, Alder Laura, Schrock Alexa B, Venstrom Jeffrey M, Knutson Keith L, Thompson E Aubrey, McGregor Kim, Sokol Ethan, Chumsri Saran |
| Molecular and clinicopathological characteristics of ERBB2 gene fusions in 32,131 Chinese patients with solid tumors. Frontiers in oncology 2022 10 12 986674. Guan Yin, Wang Yutong, Li Hongxia, Meng Jing, You Xia, Zhu Xiaofeng, Zhang Qin, Sun Tingting, Qi Chuang, An Guangyu, Fan Ying, Xu Bing |
| Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials. Annals of oncology : official journal of the European Society for Medical Oncology 2023 9 . F André, F Su, N Solovieff, G Hortobagyi, S Chia, P Neven, A Bardia, D Tripathy, Y-S Lu, A Lteif, T Taran, N Babbar, D Slamon, C L Artea |
| Association of ADME gene polymorphisms on toxicity to CDK4/6 inhibitors in patients with HR+ HER2- metastatic breast cancer. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2023 9 167 115479. Elena Peruzzi, Lorenzo Gerratana, Marcella Montico, Bianca Posocco, Serena Corsetti, Michele Bartoletti, Sara Gagno, Marco Orleni, Elena De Mattia, Massimo Baraldo, Erika Cecchin, Fabio Puglisi, Giuseppe Toffoli, Rossana Ronca |
| Overall signature of acquired KRAS gene changes in advanced non-small cell lung cancer patient with EGFR-TKI resistance. Japanese journal of clinical oncology 2023 9 . Jie Zheng, Yuanyao Dou, Daijuan Huang, Yubo Wang, Rui Han, Chen Hu, Mengxiao Zhu, Conghua Lu, Caiyu Lin, Di Wu, Yihui Liu, Huan Tang, Tingting He, Weilin Jiang, Yong |
| Prevalence of PIK3CA mutations in Taiwanese patients with breast cancer: a retrospective next-generation sequencing database analysis. Frontiers in oncology 2023 9 13 1192946. Ta-Chung Chao, Yi-Fang Tsai, Chun-Yu Liu, Pei-Ju Lien, Yen-Shu Lin, Chin-Jung Feng, Yen-Jen Chen, Jiun-I Lai, Chih-Yi Hsu, Jiun Jen Lynn, Chi-Cheng Huang, Ling-Ming Tse |
| High- and intermediate-risk susceptibility variants in melanoma families from the Mediterranean area: a multicenter cohort from the MelaNostrum Consortium. Journal of the European Academy of Dermatology and Venereology : JEADV 2023 8 . C Pellegrini, L Cardelli, P Ghiorzo, L Pastorino, M Potrony, Z García-Casado, L Elefanti, I Stefanaki, M Mastrangelo, S Necozione, P Aguilera, A Rodríguez-Hernández, L Di Nardo, T Rocco, L Del Regno, C Badenas, C Carrera, J Malvehy, C Requena, J Bañuls, A J Stratigos, K Peris, C Menin, D Calista, E Nagore, S Puig, M T Landi, M C Fargno |
| Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. Annals of oncology : official journal of the European Society for Medical Oncology 2023 8 . K Jhaveri, L D Eli, H Wildiers, S A Hurvitz, A Guerrero-Zotano, N Unni, A Brufsky, H Park, J Waisman, E S Yang, I Spanggaard, S Reid, M E Burkard, S Vinayak, A Prat, M Arnedos, F-C Bidard, S Loi, J Crown, M Bhave, S A Piha-Paul, J M Suga, S Chia, C Saura, J Á Garcia-Saenz, V Gambardella, M J de Miguel, E N Gal-Yam, A Rapael, S M Stemmer, C Ma, A B Hanker, D Ye, J W Goldman, R Bose, L Peterson, J S K Bell, A Frazier, D DiPrimeo, A Wong, C L Arteaga, D B Sol |
| Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase Inhibitors. International journal of molecular sciences 2023 7 24 (14): . Jesús Fuentes-Antrás, Ana Martínez-Rodríguez, Kissy Guevara-Hoyer, Igor López-Cade, Víctor Lorca, Alejandro Pascual, Alicia de Luna, Carmen Ramírez-Ruda, Jennifer Swindell, Paloma Flores, Ana Lluch, David W Cescon, Pedro Pérez-Segura, Alberto Ocaña, Frederick Jones, Fernando Moreno, Vanesa García-Barberán, José Ángel García-Sáe |
| Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancer. Genome medicine 2023 7 15 (1): 55. Yeon Hee Park, Seock-Ah Im, Kyunghee Park, Ji Wen, Kyung-Hun Lee, Yoon-La Choi, Won-Chul Lee, Ahrum Min, Vinicius Bonato, Seri Park, Sripad Ram, Dae-Won Lee, Ji-Yeon Kim, Su Kyeong Lee, Won-Woo Lee, Jisook Lee, Miso Kim, Hyun Seon Kim, Scott L Weinrich, Han Suk Ryu, Tae Yong Kim, Stephen Dann, Yu-Jin Kim, Diane R Fernandez, Jiwon Koh, Shuoguo Wang, Song Yi Park, Shibing Deng, Eric Powell, Rupesh Kanchi Ravi, Jadwiga Bienkowska, Paul A Rejto, Woong-Yang Park, Zhengyan K |
| Clinical and Genomic Characteristics of Patients with HR+, HER2- Metastatic Breast Cancer Following Progression on a CDK4 and 6 Inhibitor. Clinical cancer research : an official journal of the American Association for Cancer Research 2023 6 . Xi Rao, Yongmei Chen, Julie Beyrer, Emily Nash Smyth, Claudia Morato Guimaraes, Lacey M Litchfield, Lee Bowman, Garreth W Lawrence, Amit Aggarwal, Fabrice And |
| Upregulation of HCFC1 expression promoted hepatocellular carcinoma progression through inhibiting cell cycle arrest and correlated with immune infiltration. Journal of Cancer 2023 6 14 (8): 1381-1397. Huaxiang Wang, Meng Yu, Chengkai Yang, Qingsong |
| Alternating 17?-Estradiol and Aromatase Inhibitor Therapies Is Efficacious in Postmenopausal Women with Advanced Endocrine-Resistant ER+ Breast Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2023 6 OF1-OF7. Gary N Schwartz, Peter A Kaufman, Karthik V Giridhar, Jonathan D Marotti, Mary D Chamberlin, Bradley A Arrick, Grace Makari-Judson, Matthew P Goetz, Shannon M Soucy, Fred Kolling, Eugene Demidenko, Todd W Mill |
| Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker Analysis. JCO precision oncology 2023 5 7 e2200531. Lorenzo Gerratana, Andrew A Davis, Marko Velimirovic, Carolina Reduzzi, Katherine Clifton, Leslie Bucheit, Whitney L Hensing, Ami N Shah, Tania Pivetta, Charles S Dai, Paolo D'Amico, Firas Wehbe, Arielle Medford, Seth A Wander, William J Gradishar, Amir Behdad, Cynthia X Ma, Fabio Puglisi, Aditya Bardia, Massimo Cristofanil |
| Efficacy of front-line treatment for hormone receptor-positive HER2-negative metastatic breast cancer with germline BRCA1/2 mutation. British journal of cancer 2023 4 . Frenel J-S, Lusque A, Delaloge S, Ferrero J-M, Bachelot T, Desmoulins I, Levy C, Eymard J-C, Gonçalves A, Patsouris A, Reynier M A Mouret, Thery M J-C, Petit T, Cabel L, Uwer L, Debled M, Chevrot M, Mailliez A, Jacot W, de La Motte Rouge |
| Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future oncology (London, England) 2023 4 . Nicholas Turner, Cynthia Huang-Bartlett, Kevin Kalinsky, Massimo Cristofanilli, Giampaolo Bianchini, Stephen Chia, Hiroji Iwata, Wolfgang Janni, Cynthia X Ma, Erica L Mayer, Yeon Hee Park, Steven Fox, Xiaochun Liu, Sasha McClain, Francois-Clement Bida |
| HR/HER2 de novo metastatic breast cancer: a true peculiar entity? Drugs in context 2023 3 12 . Torrisi Rosalba, Jacobs Flavia, Miggiano Chiara, De Sanctis Rita, Santoro Arman |
| p27Kip1 V109G as a biomarker for CDK4/6 inhibitors indication in hormone receptor-positive breast cancer. JNCI cancer spectrum 2023 2 . Mouron Silvana, Bueno Maria J, Muñoz Manuel, Torres Raul, Rodríguez Sandra, Apala Juan V, Silva Jorge, Sánchez-Bayona Rodrigo, Manso Luis, Guerra Juan, Rodriguez-Lajusticia Laura, Malon Diego, Malumbres Marcos, Quintela-Fandino Migu |
| Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients. The oncologist 2023 11 . Jiun-I Lai, Ting-Hao Kuo, Kuan-Jung Huang, Laura Min Xuan Chai, Mei-Hsuan Lee, Chun-Yu Liu, Yi-Fang Tsai, Chi-Cheng Huang, Ling-Ming Tseng, Cheng-Chih Hsu, Ta-Chung Ch |
| Characterization of Potential Melanoma Predisposition Genes in High-Risk Brazilian Patients. International journal of molecular sciences 2023 11 24 (21): . Bianca Costa Soares de Sá, Luciana Facure Moredo, Giovana Tardin Torrezan, Felipe Fidalgo, Érica Sara Souza de Araújo, Maria Nirvana Formiga, João Pereira Duprat, Dirce Maria Carra |
| Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program. Oncogene 2023 1 . Bello Roufai D, Gonçalves A, De La Motte Rouge T, Akla S, Blonz C, Grenier J, Gligorov J, Saghatchian M, Bailleux C, Simon H, Desmoulins I, Tharin Z, Renaud E, Bertho M, Benderra M-A, Delaloge S, Robert L, Cottu P, Pierga J Y, Loirat D, Bertucci A, Renouf B, Bidard F C, Lerebours |
| Oncogenic signaling pathways and hallmarks of cancer in Korean patients with acral melanoma. Computers in biology and medicine 2023 1 154 106602. Moon SeongRyeol, Kim Hee Joo, Lee Yeeun, Lee Yu Joo, Jung Sungwon, Lee Jin Sook, Hahn Si Houn, Kim Kyungdoc, Roh Joo Young, Nam Seungyo |
| Genomic complexity predicts resistance to endocrine therapy and CDK4/6 inhibition in hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 2023 1 . Davis Andrew A, Luo Jingqin, Zheng Tiantian, Dai Chao, Dong Xiaoxi, Tan Lu, Suresh Rama, Ademuyiwa Foluso O, Rigden Caron, Rearden Timothy P, Clifton Katherine, Weilbaecher Katherine, Frith Ashley, Tandra Pavankumar K, Summa Tracy, Haas Brittney, Thomas Shana, Hernandez-Aya Leonel F, Peterson Lindsay L, Wang Xiaohong, Luo Shujun J, Zhou Kemin, Du Pan, Jia Shidong, King Bonnie L, Krishnamurthy Jairam, Ma Cynthia |
| Cerebrospinal fluid-derived circulating tumor DNA is more comprehensive than plasma in NSCLC patients with leptomeningeal metastases regardless of extracranial evolution. Heliyon 2023 1 8 (12): e12374. Yang Hainan, Wen Lei, Zhao Chao, Chen Jianing, Zhou Zhaoming, Zhou Cheng, Cai Linbo, Zhou Caic |
- Page last reviewed:Oct 1, 2023
- Page last updated:Dec 01, 2023
- Content source: